Key Points
- SiBone CFO Anshul Maheshwari has sold a total of 10,672 shares in recent transactions (including 1,200 shares on Nov. 21), generating roughly $181,012 in proceeds.
- After the Nov. 21 sale he still owns 203,873 shares valued at about $4.08 million, with that single trade reducing his stake by 0.59%.
- For context, SiBone (NASDAQ:SIBN) is trading near its 12‑month high (~$19.67–$20.05), has a market cap of about $853M, reported EPS of -$0.11 last quarter (beating estimates), and carries a consensus analyst rating of Moderate Buy with a $23 price target.
SiBone (NASDAQ:SIBN - Get Free Report) CFO Anshul Maheshwari sold 1,200 shares of the company's stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $20.01, for a total transaction of $24,012.00. Following the sale, the chief financial officer owned 203,873 shares in the company, valued at $4,079,498.73. The trade was a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Anshul Maheshwari also recently made the following trade(s):
- On Tuesday, November 25th, Anshul Maheshwari sold 100 shares of SiBone stock. The stock was sold at an average price of $20.00, for a total transaction of $2,000.00.
- On Monday, November 17th, Anshul Maheshwari sold 3,460 shares of SiBone stock. The shares were sold at an average price of $17.43, for a total transaction of $60,307.80.
- On Tuesday, November 11th, Anshul Maheshwari sold 2,601 shares of SiBone stock. The shares were sold at an average price of $18.33, for a total transaction of $47,676.33.
- On Thursday, October 2nd, Anshul Maheshwari sold 3,311 shares of SiBone stock. The stock was sold at an average price of $14.20, for a total transaction of $47,016.20.
SiBone Stock Performance
NASDAQ:SIBN opened at $19.67 on Wednesday. The firm has a market capitalization of $853.48 million, a PE ratio of -38.57 and a beta of 0.81. The business's fifty day moving average price is $15.76 and its 200 day moving average price is $16.80. The company has a debt-to-equity ratio of 0.21, a current ratio of 7.97 and a quick ratio of 6.62. SiBone has a 12 month low of $12.49 and a 12 month high of $20.05.
SiBone (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. The company had revenue of $48.66 million during the quarter, compared to the consensus estimate of $46.67 million. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%. SiBone has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that SiBone will post -0.78 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. State of Alaska Department of Revenue acquired a new stake in shares of SiBone during the third quarter worth about $39,000. State of Wyoming acquired a new stake in SiBone during the 2nd quarter worth approximately $55,000. Virtus Advisers LLC purchased a new position in shares of SiBone in the 1st quarter valued at approximately $58,000. Canada Pension Plan Investment Board purchased a new stake in shares of SiBone during the second quarter worth approximately $68,000. Finally, Quarry LP lifted its holdings in shares of SiBone by 862.6% during the third quarter. Quarry LP now owns 4,861 shares of the company's stock worth $72,000 after purchasing an additional 4,356 shares during the period. 98.11% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on SIBN shares. Cantor Fitzgerald set a $25.00 price target on shares of SiBone and gave the company an "overweight" rating in a research note on Monday, August 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SiBone in a research note on Wednesday, November 19th. Wall Street Zen cut shares of SiBone from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Truist Financial dropped their price objective on SiBone from $22.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, October 15th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $23.00.
Get Our Latest Research Report on SiBone
About SiBone
(
Get Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
